Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.

Satoshi YukiKatsunori ShinozakiTomomi KashiwadaTetsuya KusumotoMasaaki IwatsukiHironaga SatakeKazuma KobayashiTaito EsakiYuichiro NakashimaHirofumi KawanakaYasunori EmiYoshito KomatsuMototsugu ShimokawaAkitaka MakiyamaHiroshi SaekiEiji OkiHideo BabaMasaki Mori

Published in: Cancer chemotherapy and pharmacology (2019)

T-SOX130 showed promising response and survival with a favorable safety profile and should be considered for patients with HER2+ AGC.

Keyphrases

phase ii study
transcription factor
stem cells
open label
locally advanced
squamous cell carcinoma
small cell lung cancer
epidermal growth factor receptor
placebo controlled
double blind
cross sectional
rectal cancer
clinical trial
metastatic breast cancer
free survival
radiation therapy
tyrosine kinase